SeQuent® Please OTWPeripheral drug coated balloon catheter

SeQuent® Please OTW features an optimized and clinically proven drug-coating technology which facilitates the safe and effective treatment of patients with peripheral arterial disease (PAD) in above and below the knee indications. [1, 2]

As pioneers and global market leaders in drug-coated balloon catheter technologies that help interventionalists achieve the treatment strategy of leaving (almost) nothing behind, B. Braun brings extensive knowledge to the peripheral field with the SeQuent® Please OTW.

An effective next generation combination of Paclitaxel and Resveratrol [1,2]

SeQuent® Please OTW features an optimized and clinically proven drug-coating technology which facilitates the safe and effective treatment of patients with peripheral arterial disease.

Long-term efficacy with short-term drug release [1,2]

  • Paclitaxel with an effective drug dose of 3μg/mm² [3,4]
  • Significant reduction of TLR and in late lumen loss (LLL) compared to uncoated balloons [1,2,5]

Resveratrol: A naturally occurring matrix builder

  • Naturally occurring, plant-based substance found for example in the skin of red grapes & raspberries [5]
  • Acts as matrix builder and makes the Paclitaxel bioavailable [5]
  • Enables fast and effective drug transfer into vessel wall [5]

Mechanically resistant coating (5)

  • Homogeneous coating even in the balloon folds exceeding distal and proximal markers [5]
  • Low drug loss in simulated use [5]
  • Efficient available drug dose at inflation [1,2,5]

CONSEQUENT Demonstrates Safety and Efficacy

Safety and efficacy of SeQuent® Please OTW was demonstrated in an unselected, all comers cohort [2] whereas two-year efficacy and safety was shown in the CONSEQUENT RCT [1,4].

Read more

SeQuent® Please OTW features an optimized and clinically proven drug-coating technology which facilitates the safe and effective treatment of patients with peripheral arterial disease (PAD) in above and below the knee indications. [1, 2]

As pioneers and global market leaders in drug-coated balloon catheter technologies that help interventionalists achieve the treatment strategy of leaving (almost) nothing behind, B. Braun brings extensive knowledge to the peripheral field with the SeQuent® Please OTW.

An effective next generation combination of Paclitaxel and Resveratrol [1,2]

SeQuent® Please OTW features an optimized and clinically proven drug-coating technology which facilitates the safe and effective treatment of patients with peripheral arterial disease.

Long-term efficacy with short-term drug release [1,2]

  • Paclitaxel with an effective drug dose of 3μg/mm² [3,4]
  • Significant reduction of TLR and in late lumen loss (LLL) compared to uncoated balloons [1,2,5]

Resveratrol: A naturally occurring matrix builder

  • Naturally occurring, plant-based substance found for example in the skin of red grapes & raspberries [5]
  • Acts as matrix builder and makes the Paclitaxel bioavailable [5]
  • Enables fast and effective drug transfer into vessel wall [5]

Mechanically resistant coating (5)

  • Homogeneous coating even in the balloon folds exceeding distal and proximal markers [5]
  • Low drug loss in simulated use [5]
  • Efficient available drug dose at inflation [1,2,5]

CONSEQUENT Demonstrates Safety and Efficacy

Safety and efficacy of SeQuent® Please OTW was demonstrated in an unselected, all comers cohort [2] whereas two-year efficacy and safety was shown in the CONSEQUENT RCT [1,4].

References

[1] Albrecht T et al. Cardiovasc Intervent Radiol. 2018 Jul;41(7):1008-14.[2] Langhoff R et al. Angiology. 2021 Mar 29:3319721997314.[3] Tepe G et al. N Engl J Med. 2008 Feb 14;358(7):689-99.[4] Tepe G et al. Cardiovasc Intervent Radiol. 2017 Oct;40(10):1535-44.[5] Data on file at B. Braun.